Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nuvation BioNUVB +8.19%33 PB Ratio is 6.83 as of Jul. 20, 2026, which is 145% above its 10-year median of 2.79. GuruFocus rates NUVB with a GF Score™ of 33/100. The stock has 3 warning signs investors should review. Among 1,231 Biotechnology companies, Nuvation Bio ranks worse than 75.55% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-20), Nuvation Bio's share price is $6.275. Nuvation Bio's Book Value per Share for the quarter that ended in Mar. 2026 was $0.92. Hence, Nuvation Bio's PB Ratio of today is 6.83.
The historical rank and industry rank for Nuvation Bio's PB Ratio or its related term are showing as below:
NUVB'
s PB Ratio Range Over the Past 10 Years
Min: 1.33 Med: 2.79 Max: 9.93
Current: 6.82
During the past 6 years, Nuvation Bio's highest PB Ratio was 9.93. The lowest was 1.33. And the median was 2.79.
NUVB's PB Ratio is ranked worse than 75.55% of 1231
companies
in the Biotechnology industry
Industry Median: 2.82
vs NUVB: 6.82
During the past 12 months, Nuvation Bio's average Book Value Per Share Growth Rate was -25.50% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -33.50% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -9.20% per year.
During the past 6 years, the highest 3-Year average Book Value Per Share Growth Rate of Nuvation Bio was 40.90% per year. The lowest was -33.50% per year. And the median was -26.30% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Nuvation Bio PB Ratio Related Terms
Nuvation Bio PB Ratio Historical Data
* Premium members only.
The historical data trend for Nuvation Bio's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Nuvation Bio's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nuvation Bio PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nuvation Bio's PB Ratio distribution charts can be found below:
* The bar in red indicates where Nuvation Bio's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Nuvation Bio's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Nuvation Bio (NUVB) has a PB Ratio of 6.83 as of Jul. 20, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Nuvation Bio and its competitors. This is 145% above median its historical median of 2.79. Over the past decade, Nuvation Bio's PB Ratio has ranged from 1.33 to 9.93. According to the industry distribution chart, Nuvation Bio ranks #930 out of 1231 companies in the Biotechnology industry, placing it in the top 75.5%.
Is Nuvation Bio's PB Ratio too high?
Nuvation Bio's current PB Ratio of 6.83 is 145% above median its 10-year median of 2.79. Over the past 10 years, this metric has ranged from a low of 1.33 to a high of 9.93. The Biotechnology industry median PB Ratio is 2.82. Nuvation Bio's value of 6.83 is 142.2% above this industry median. Based on the distribution chart, Nuvation Bio ranks #930 out of 1231 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Nuvation Bio has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Nuvation Bio's PB Ratio compare to VRDN and STOK?
According to the Biotechnology industry distribution chart, Nuvation Bio ranks #930 out of 1231 companies for PB Ratio. This places Nuvation Bio in the lower half of its industry. The industry median PB Ratio is 2.82. Nuvation Bio's value of 6.83 is 142.2% above this benchmark. Historically, Nuvation Bio's own PB Ratio has ranged from 1.33 to 9.93 over the past decade. While the company's 10-year median is 2.79 vs. the industry median of 2.82, Nuvation Bio has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.82, based on 1,231 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nuvation Bio's current PB Ratio of 6.83 is 142.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Nuvation Bio and its competitors. For the Biotechnology industry, the median PB Ratio is 2.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nuvation Bio's current PB Ratio is 6.83, which is 145% above median its own 10-year median of 2.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nuvation Bio stock overvalued right now?
Nuvation Bio (NUVB) has a current PB Ratio of 6.83. The current PB Ratio is 6.83, which is 145% above median its 10-year median of 2.79 and 142.2% above the Biotechnology industry median of 2.82. Nuvation Bio's overall GF Score™ is 33/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Nuvation Bio (NUVB), the current PB Ratio is 6.83 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.
33GF Score
Get the complete analysis for NUVB
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NUVB has been successfully added to your 
